Compare AIRI & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRI | INTS |
|---|---|---|
| Founded | 1979 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 13.7M |
| IPO Year | 2013 | 2021 |
| Metric | AIRI | INTS |
|---|---|---|
| Price | $2.48 | $3.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.33 |
| AVG Volume (30 Days) | 7.8K | ★ 21.0K |
| Earning Date | 11-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.39 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $47,921,000.00 | N/A |
| Revenue This Year | $4.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.30 | $0.22 |
| 52 Week High | $3.95 | $8.06 |
| Indicator | AIRI | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 45.77 | 36.95 |
| Support Level | $2.50 | $3.15 |
| Resistance Level | $2.75 | $4.17 |
| Average True Range (ATR) | 0.09 | 0.34 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 14.82 | 10.53 |
Air Industries Group is an aerospace and defense company. Its manufacturers of precision components and assemblies for large aerospace and defense prime contractors. The company products include landing gears, flight controls, engine mounts and components for aircraft jet engines, ground turbines and other complex machines. The ultimate end-user of products is the U.S. Government, international governments, and commercial global airlines.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.